Immuno-oncology
Conference Coverage
Dr. Louis Weiner: AACR presentations highlight new “transformative strategies”
ATLANTA – Studies featured during a press briefing at the AACR annual meeting, including work on a cancer preventive...
Conference Coverage
Preclinical findings highlight value of Lynch syndrome for cancer vaccine development
ATLANTA – Lynch syndrome is serving as a platform for the development of immunoprevention cancer vaccines.
Conference Coverage
CAR T cells target HER2 expression in advanced sarcomas
ATLANTA – Although HER2 expression in osteosarcoma and rhabomyosarcoma is too low for HER2-targeted therapies such...
Conference Coverage
Combo may improve PFS, OS for certain ovarian cancer patients
HONOLULU - Combining avelumab with pegylated liposomal doxorubicin may provide a survival benefit in certain patients with platinum-resistant or...
Conference Coverage
Novel immunostimulant combo shows early efficacy
SAN FRANCISCO – A one-two approach to stimulating both innate and adaptive immunity appears to be paying off, suggest early efficacy data from a...
Conference Coverage
Antibiotics gut checkpoint inhibitor efficacy
SAN FRANCISCO – Patients who had received antibiotics more than a month before a checkpoint inhibitor had significantly worse survival, regardless...
Conference Coverage
Pembrolizumab/lenvatinib active against urothelial carcinoma
SAN FRANCISCO – Early objective responses were sufficient to prompt a larger phase 3 trial of the TKI and immune checkpoint inhibitor combination...
Conference Coverage
Higher dose of checkpoint inhibitor every 4 weeks feasible in NSCLC
SAN FRANCISCO – The 6-month PFS rates were similar for patients treated every 2 or 4 weeks, but the trial could not show noninferiority of...
Conference Coverage
Diet appears to play an important role in response to anti-PD-1 cancer immunotherapy
Diet appears to affect response to anti-PD-1 cancer immunotherapy, likely by its effect on the gut microbiome.
Feature
Barriers to CAR T use in the spotlight at first European meeting
European approvals of CAR T-cell therapy are prompting a closer look at economic issues, outcomes data, and future directions.
From the Journals
Model shows nivolumab plus ipilimumab cost effective in mRCC
A subgroup analysis indicated that nivolumab plus ipilimumab was most cost effective for patients with 1% or greater PD-L1 expression.